Folegatti, Pedro M <br/><br/>
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.  [electronic resource] 

 -  The Lancet. Infectious diseases  07 2020 
 - 816-826 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-4457 
<br/><br/><label>Standard No.: </label>10.1016/S1473-3099(20)30160-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Neutralizing--immunology<br/>Antibodies, Viral<br/>Coronavirus Infections--prevention & control<br/>Dose-Response Relationship, Immunologic<br/>Enzyme-Linked Immunosorbent Assay<br/>Female<br/>Humans<br/>Immunogenicity, Vaccine<br/>Male<br/>Middle Aged<br/>Middle East Respiratory Syndrome Coronavirus--genetics<br/>United Kingdom<br/>Vaccines, DNA<br/>Viral Vaccines--administration & dosage<br/>Young Adult